SEC filing summary
Company identity discrepancy: The request identifies Bio Green Med Solution, Inc., but the supplied Form 10-Q is for Cyclacel Pharmaceuticals, Inc. This summary reflects the filing text, not the company named in the request.
Business context and reporting period
Unaudited Form 10-Q for the quarter and nine months ended September 30, 2011. Cyclacel describes itself as a development-stage biopharmaceutical company focused on cancer treatments. Its lead candidate, sapacitabine, was in a Phase 3 AML trial; it also had earlier-stage programs and marketed three products for radiation dermatitis and xerostomia.
Financial performance and position
Amounts are in $000s unless stated otherwise.
| Metric | Three months ended Sept. 30 | Nine months ended Sept. 30 |
|---|---|---|
| Revenue | 2011: $164; 2010: $159 | 2011: $524; 2010: $548 |
| Cost of goods sold | 2011: $95; 2010: $76 | 2011: $273; 2010: $310 |
| Research and development | 2011: $2,066; 2010: $1,469 | 2011: $7,005; 2010: $4,968 |
| Selling, general and administrative | 2011: $2,051; 2010: $2,612 | 2011: $5,891; 2010: $8,103 |
| Operating loss | 2011: $(4,048); 2010: $(3,998) | 2011: $(12,645); 2010: $(12,833) |
| Net loss | 2011: $(3,445); 2010: $(3,807) | 2011: $(11,585); 2010: $(12,849) |
| Net loss applicable to common shareholders | 2011: $(3,627); 2010: $(3,989) | 2011: $(12,131); 2010: $(16,349) |
| Basic and diluted loss per share | 2011: $(0.07); 2010: $(0.11) | 2011: $(0.25); 2010: $(0.47) |
| Net cash used in operating activities | Not stated for quarter | 2011: $(10,718); 2010: $(12,302) |
Product gross profit was $69,000 for the quarter and $251,000 for the nine months, equivalent to approximate gross margins of 42% and 48%, respectively. These are calculated from reported product revenue and cost of goods sold.
At September 30, 2011, cash and cash equivalents were $27.675 million, total current assets $28.781 million, current liabilities and total liabilities $5.935 million, and working capital $22.846 million. Total assets were $28.946 million; stockholders’ equity was $23.011 million. The balance sheet reports no long-term liabilities or funded debt. Accumulated development-stage deficit was $253.406 million. Cash declined $1.820 million from year-end 2010. Management said existing funds and expected cash flows were sufficient for planned needs for at least 12 months.
Material changes versus prior comparable period
- Nine-month R&D expense rose 41% to $7.005 million, primarily from increased sapacitabine trial activity and a $1.6 million Daiichi Sankyo milestone payment triggered by SEAMLESS enrollment.
- Nine-month SG&A fell 27% to $5.891 million, mainly due to lower professional, personnel, rent and stock-compensation costs.
- Nine-month revenue fell 4%: product revenue increased 21% to $524,000, but collaboration and grant revenue were nil versus $116,000 combined in 2010.
- Operating cash use improved by $1.584 million. Financing provided $8.897 million in the first nine months of 2011, including approximately $9.3 million net proceeds from a July stock-and-warrant offering; the comparable 2010 period included substantially larger financing inflows.
- Common shares outstanding increased to 54.213 million from 46.565 million at year-end 2010. Warrants outstanding totaled 13.814 million shares at September 30, 2011.
Outlook, risks and unusual items
- The SEAMLESS independent safety board recommended proceeding to the randomized stage. In October 2011, Cyclacel changed the design from three arms to two; the FDA confirmed the existing Special Protocol Assessment remained valid. Management anticipated higher 2011 R&D spending as the Phase 3 trial enrolled.
- Management expected no grant revenue for the remainder of 2011 and expected SG&A to remain below 2010 levels. It said significant product revenue was not expected until a candidate received regulatory approval and was commercialized.
- The company reported a NASDAQ minimum-bid-price deficiency: shares had closed below $1 for 30 consecutive business days. It had until March 14, 2012 to regain compliance, or risk delisting.
- On October 6, 2011, the board did not declare the third-quarter 2011 cash dividend on 6% convertible preferred stock. Unpaid cumulative dividends increase the preferred stock’s liquidation preference; the filing reported $1.4 million accrued and unpaid at September 30. Preferred holders had elected two board members after six quarterly dividends went unpaid.
- Major risks include clinical-trial failure or delay, regulatory uncertainty, reliance on external funding and third-party manufacturers, concentrated product sales through three wholesalers, competition, intellectual-property exposure, and potential dilution from equity and warrants. The filing also describes ongoing patent litigation with Celgene involving four Cyclacel patents.
- Management concluded disclosure controls were not effective at the reasonable-assurance level because previously identified material weaknesses remained. Remediation efforts included hiring finance personnel and outside consultants; management warned remediation could add costs.
- Warrant-liability remeasurement produced a $643,000 gain for the nine months, a noncash item that contributed to reported results. The July 2011 offering raised approximately $9.3 million net and included five-year warrants.
Important facts for investors to verify
- Confirm the filing’s issuer is Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc.
- Review the latest SEAMLESS enrollment, trial design, safety and efficacy updates, and the FDA’s SPA status.
- Assess cash burn, the basis for management’s stated 12-month funding outlook, and the timing and terms of any additional financing.
- Check NASDAQ bid-price compliance and the potential effect of delisting on liquidity and access to capital.
- Verify preferred dividend arrears, related board-election rights, and the potential dilution from outstanding warrants and preferred-stock conversion.
- Review the status and potential financial impact of the Celgene litigation and the remediation of internal-control weaknesses.